BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33686252)

  • 1. Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.
    Williams L; Doucette K; Karp JE; Lai C
    Bone Marrow Transplant; 2021 Jul; 56(7):1535-1549. PubMed ID: 33686252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
    Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
    Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-derived myelodysplastic syndrome after allogeneic stem cell transplantation in a family with germline GATA2 mutation.
    Sakata N; Okano M; Masako R; Tanaka A; Yamashita Y; Karasuno T; Imadome KI; Okada M; Sugimoto K
    Int J Hematol; 2021 Feb; 113(2):290-296. PubMed ID: 32865708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia.
    Schwartz JR; Walsh MP; Ma J; Lamprecht T; Wang S; Wu G; Raimondi S; Triplett BM; Klco JM
    Cold Spring Harb Mol Case Stud; 2018 Oct; 4(5):. PubMed ID: 29891567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature.
    Wang E; Hutchinson CB; Huang Q; Lu CM; Crow J; Wang FF; Sebastian S; Rehder C; Lagoo A; Horwitz M; Rizzieri D; Yu J; Goodman B; Datto M; Buckley P
    Am J Clin Pathol; 2011 Apr; 135(4):525-40. PubMed ID: 21411775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.
    Potter VT; Krishnamurthy P; Barber LD; Lim Z; Kenyon M; Ireland RM; de Lavallade H; Dhouri A; Marsh JC; Marcus R; Devereux S; Ho A; Pagliuca A; Mufti GJ
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):111-7. PubMed ID: 24216184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study.
    Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q
    Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor cell leukemia/myelodysplastic syndrome after allogeneic stem cell transplantation: a rare phenomenon with more challenges for hematologists.
    Zhang S; Li L; Cao W; Li Y; Jiang Z; Yu J; Wan D
    Hematology; 2021 Dec; 26(1):648-651. PubMed ID: 34474660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 13. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.
    West AH; Godley LA; Churpek JE
    Ann N Y Acad Sci; 2014 Mar; 1310(1):111-8. PubMed ID: 24467820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
    Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 17. Donor-derived MDS/AML in families with germline
    Galera P; Hsu AP; Wang W; Droll S; Chen R; Schwartz JR; Klco JM; Arai S; Maese L; Zerbe C; Parta MJ; Young NS; Holland SM; Hickstein DD; Calvo KR
    Blood; 2018 Nov; 132(18):1994-1998. PubMed ID: 30232126
    [No Abstract]   [Full Text] [Related]  

  • 18. Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.
    Arai H; Matsui H; Chi S; Utsu Y; Masuda S; Aotsuka N; Minami Y
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
    Yang G; Wang X; Huang S; Huang R; Wei J; Wang X; Zhang X
    Front Immunol; 2022; 13():1034438. PubMed ID: 36268012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.